Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal vs Topical Testosterone in Secondary Hypogonadism
NCT00706719Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Jun 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enclomiphene in secondary hypogonadism (HH) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoints: Sperm Concentration at Month 7, Motile Total Sperm Count at Month 7 and 1 more. Started Jun 2008; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT00706719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706719.